Follicular Lymphoma

• EMA withdrawal · 2026-04-09
  EMA Withdrawn: Copiktra (duvelisib) — Secura Bio Limited

  The European Medicines Agency has withdrawn the marketing authorization for Copiktra (duvelisib) from Secura Bio Limited; the drug for chron…

• CLINICAL_TRIALS withdrawal · 2026-03-18
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma [Phase 3]

  A Phase 3 trial evaluating lisocabtagene maraleucel (Liso-cel) versus standard of care in adults with relapsed or refractory follicular lymp…

• CLINICAL_TRIALS withdrawal · 2026-01-30
  Clinical Trial Update: A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation [Phase 2]

  Phase 2 trial of oral tazemetostat for relapsed/refractory follicular lymphoma without EZH2 gain-of-function mutation has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2025-06-12
  Clinical Trial Update: Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. [NA]

  A clinical trial evaluating Triamcinolone acetonide injections with a novel needle-free delivery system for primary cutaneous lymphoma plaqu…

• CLINICAL_TRIALS withdrawal · 2025-05-06
  Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]

  Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2025-02-03
  Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]

  A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.

• EMA withdrawal · 2024-07-10
  EMA Lapsed: Zevalin (ibritumomab tiuxetan) — Ceft Biopharma s.r.o.

  The EMA indicates Zevalin (ibritumomab tiuxetan) marketing authorization in the EU has lapsed. The MAH is Ceft Biopharma s.r.o., and the the…

• CLINICAL_TRIALS withdrawal · 2024-07-08
  Clinical Trial Update: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma [Phase 1, Phase 2]

  The GEMHDM2014 trial evaluating Gem-HDM HDT and autologous stem cell transplant for relapsed/refractory lymphoma has been terminated after P…

• CLINICAL_TRIALS withdrawal · 2024-04-25
  Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]

  A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…

• CLINICAL_TRIALS withdrawal · 2022-07-18
  Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) [Phase 3]

  A Phase 3 clinical trial evaluating parsaclisib with rituximab or obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone …

• CLINICAL_TRIALS withdrawal · 2021-03-17
  Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]

  Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.

• CLINICAL_TRIALS withdrawal · 2020-12-17
  Clinical Trial Update: Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. [Phase 3]

  A Phase 3 trial comparing HLX01 to Mabthera in CD20-positive follicular lymphoma with low tumor burden was withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-12-02
  Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]

  A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…

• CLINICAL_TRIALS withdrawal · 2017-05-19
  Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

  The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…

• CLINICAL_TRIALS withdrawal · 2016-08-11
  Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…

• CLINICAL_TRIALS withdrawal · 2015-10-12
  Clinical Trial Update: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas [Phase 2]

  This clinical trial update notes that the Phase 2 study of the anti-CD20 antibody ofatumumab in older patients with untreated indolent B-cel…

• CLINICAL_TRIALS withdrawal · 2015-09-25
  Clinical Trial Update: Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma [Phase 1, Phase 2]

  The clinical trial of lenalidomide for previously untreated advanced-stage follicular lymphoma has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-04-21
  Clinical Trial Update: Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma [Phase 1, Phase 2]

  The Phase 1/2 clinical trial evaluating HuMax-CD20 for early-stage follicular lymphoma has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-04-17
  Clinical Trial Update: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Phase 3]

  A Phase 3 trial comparing two radioimmunotherapy regimens (I-131 tositumomab vs ibritumomab tiuxetan) for follicular and other non-Hodgkin l…

• CLINICAL_TRIALS withdrawal · 2015-01-19
  Clinical Trial Update: Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma [Phase 3]

  A Phase 3 trial evaluating pixantrone in combination with rituximab for indolent non-Hodgkin lymphoma was terminated.

• CLINICAL_TRIALS withdrawal · 2013-06-06
  Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…